【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2013 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2013 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2013 18
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2013 19
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2013 20
2.4.1 McKesson to Acquire Celesio for US$8.49 Billion 20
2.4.2 AstraZeneca to Acquire Remaining 50% Interest in Diabetes Joint Venture from Bristol-Myers Squibb for US$4.3 Billion 22
2.4.3 Shire Completes Acquisition of Majority Interest in ViroPharma for US$2.7 Billion 23
2.4.4 Johnson & Johnson Prices Public Offering of Notes for US$3.5 Billion 24
2.4.5 OncoMed Pharma Enters Into Co-Development Agreement with Celgene 24
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 26
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q4 2013 26
3.1.1 Top M&A Deals in Q4 2013 27
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2012 – Q4 2013 28
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2013 30
3.2.1 Top Initial Public Offerings in Q4 2013 32
3.2.2 Top Secondary Offerings in Q4 2013 32
3.2.3 Top PIPE Deals in Q4 2013 32
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2012-Q4 2013 33
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2012 – Q4 2013 34
3.2.6 Top Venture Financing Deals in Q4 2013 36
3.2.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2013 37
3.2.8 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2013 38
3.2.9 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2012 – Q4 2013 39
3.2.10 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2012 – Q4 2013 41
3.2.11 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2012 – Q4 2013 43
3.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2013 44
3.3.1 Top Private Equity Deals in Q4 2013 45
3.3.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2012 – Q4 2013 46
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2013 48
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2013 48
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2012 – Q4 2013 50
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 52
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2013 53
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2013 54
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2013 55
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 – Q4 2013 56
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2012 – Q4 2013 58
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2012 – Q4 2013 59
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 – Q4 2013 61
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2013 63
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2013 63
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 – Q4 2013 65
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2013 67
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2013 67
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2013 68
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2012 – Q4 2013 69
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2012 – Q4 2013 71
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2012 – Q4 2013 73
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2012 – Q4 2013 74
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2012 – Q4 2013 76
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 78
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q4 2012 – Q4 2013 78
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q4 2012 – Q4 2013 80
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2012 – Q4 2013 82
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2012 – Q4 2013 84
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q4 2012 – Q4 2013 86
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q4 2012 – Q4 2013 88
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2012 – Q4 2013 90
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2013 92
7.1.1 Oncology – Deals of the Quarter 94
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2013 97
7.2.1 Central Nervous System – Deals of the Quarter 99
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2013 101
7.3.1 Infectious Disease – Deals of the Quarter 103
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2013 104
7.4.1 Immunology – Deals of the Quarter 106
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2013 107
7.5.1 Metabolic Disorders – Deals of the Quarter 109
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2013 111
7.6.1 Cardiovascular – Deals of the Quarter 113
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2013 115
7.7.1 Gastrointestinal – Deals of the Quarter 117
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2013 119
7.8.1 Dermatology – Deals of the Quarter 121
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2013 122
7.9.1 Respiratory – Deals of the Quarter 124
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q4 2013 126
7.10.1 Ophthalmology – Deals of the Quarter 128
8 Deal Summary by Geography 129
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2013 129
8.1.1 North America – Deals of the Quarter 131
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2013 134
8.2.1 Europe – Deals of the Quarter 136
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2013 139
8.3.1 Asia-Pacific – Deals of the Quarter 141
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2013 143
8.4.1 Rest of the World – Deals of the Quarter 145
9 Pharmaceuticals & Healthcare, Global, Top Advisors 146
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 146
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 148
10 Appendix 150
11 Further Information 154
11.1 Methodology 154
11.2 About GlobalData 155
11.3 Disclosure information 156
11.4 Disclaimer 156
【レポート販売概要】
■ タイトル：グローバル製薬業界における事業提携、ライセンシング、投資及びM&A動向：Q4 2013■ 英文：Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013
■ 発行日：2014年2月28日
■ 調査会社：GlobalData
■ 商品コード：GDPH0441QD
■ 調査対象地域：グローバル
- 世界のタブレット用モーション・センサー市場動向（2012-2016）TechNavio's analysts forecast the Global Motion Sensor for Tablet market to grow at a CAGR of 51.8 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing sales of tablets. The market has also been witnessing the declining ASP of tablets. However, the emergence of phabletes could pose a challenge to the growth of this market. TechNavio's repor …
- エレクトロクロミック・ガラス及びフィルムの世界市場Electrochromic (EC) glass is already being used in considerable quantities for smart mirrors by Gentex, but NanoMarkets believes that EC glass also has considerable opportunities going forward in the smart windows market. Indeed, of the half-dozen technologies that are currently being aimed at the emerging smart windows sector, it seems likely that EC glass will do the best in the marketplace. Thi …
- Licensed and Unlicensed Spectrum Applied-Use: A Comparative AnalysisEnterprise and consumer are increasingly annoyed and bored with location-based applications that provide only adequate positioning when their needs are becoming more transparent with the rise of social media as a method for communicating their desires and disappointments. Enterprise and consumer want the most powerful positioning solutions available for mobile work and social life - including empl …
- インパクト投資の世界市場2015Impact investments have become a new investment option among HNWIs and UHNWIs worldwide. They have significantly increased in market size, despite their relatively recent development in 2007. JP Morgan and Global Impact Investing Network (GIIN) estimated the market size of impact investments at around US$46 billion in 2013. In the UK market, impact investments valued GBP200 million in 2014, and ar …
- 二酸化チタンナノ材料の世界市場2016-2020About Titanium Dioxide Nanomaterials Since the advent of nanotechnology, titanium dioxide nanomaterials have been at the center of research because of their low price and simple production process. These nanomaterials are synthesized at various purity levels from 75% to 99.97% and with diameters ranging from 5 nanometers to 250 nanometers. Although these nanomaterials are used in the commercial an …
- 果物ジュース包装の世界市場2016-2020About the Fruit Juice Packaging Market Fruit juice packaging provides product support, protection from external environmental factors, and tampering resistance. Fruit juice packaging aids in the reliable distribution of the product among the value chain and reduces post-production damage. Glass, plastic, and carton are commonly used packaging formats for fruit juices. Technavio’s analysts forecast …
- 肥大型心筋症（HCM）治療薬の世界市場2017-2021ABSTRACTAbout Hypertrophic Cardiomyopathy Therapeutics HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefo …
- メキシコの石油・ガス産業における中流（Midstream）市場展望Mexico Midstream Oil and Gas Industry Outlook to 2020: Market Forecasts for Liquefied Natural Gas (LNG), Oil Storage, Pipelines and Gas Processing Summary "Mexico Midstream Oil and Gas Industry Outlook to 2020: Market Forecasts for Liquefied Natural Gas (LNG), Oil Storage, Pipelines and Gas Processing" is a comprehensive report on midstream oil and gas industry in Mexico. The report provides oil p …
- 世界の電力産業におけるDCS（分散制御システム）市場About DCS A DCS is an automated control system that, rather than being centralized, is distributed across an entire organization. DCS is distributed in such a way that each component or sub-system of a manufacturing plant is controlled by one or more controllers, thereby providing instructions to different parts of the plant. Thus, instead of having a centrally located control system, each section …
- グローバルスキンケア製品市場におけるM&A動向（2014年3月）Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global skincare market during March 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global skincare market throughout the month. Additionally, the report provides an overview of all the partneri …
- 圧電機器の世界市場2016-2020：アクチュエータ、ピエゾジェネレータ、トランスデューサー、センサー、加速装置、ピエゾトランスフォーマー、共振器、音響装置、超音波モーターAbout PiezoelectricPiezoelectricity is the electric charge that gets collected in solid materials such as crystals or ceramics when a mechanical force is applied. Piezoelectric materials exhibit two properties: direct effect and converse effect. The phenomenon when the voltage gets induced after applying mechanical force is called direct effect, while the phenomenon of changing the crystal shape a …
- 機能性食品の世界市場2016-2026The new report from business intelligence provider visiongain offers an updated outlook for the global functional foods market and growing “superfood” trend. Visiongain assesses that the functional foods market will generate revenues of $69.45bn in 2016. Now: “Functional Food Industry Boom: Chia, Flax and Quinoa Seeds Markets Witnessing Double Digit Growth.” This is an example of the business crit …
- 世界の特殊タイヤ（自動車用）市場動向（2014-2018）About Specialty Tires Tires are an integral component of vehicles and are manufactured using raw materials such as natural rubber, nylon tire cord fabric, and carbon black. Rubber chemicals and synthetic rubber, including styrene-butadiene rubber and poly-butadiene rubber, are also used in manufacturing tires. Specialty tires are used in aircraft, two-wheelers, agricultural equipment, and in vario …
- ニッケル電池のグローバル市場動向While nickel-based batteries are not new to the market, it is only recently that they have started gaining much popularity due to their higher capacity. There are two main types of nickel-based batteries - nickel cadmium and nickel metal hydride batteries. While NiMH batteries are considered to be safer than NiCd batteries, the fact remains that both these nickel-based batteries are finding favor …
- Kuwait Energy Company K.S.C.：石油・ガスバリューチェーン分析レポート2013Kuwait Energy Company K.S.C. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Kuwait Energy Company K.S.C." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Kuwait Energy Company K.S.C.”. The report provides key information relating to oil and gas assets of the company along with its operations across the valu …
